Proposal for a Biologic Staging System of Parkinson's Disease
- PMID: 37066922
- PMCID: PMC10200239
- DOI: 10.3233/JPD-225111
Proposal for a Biologic Staging System of Parkinson's Disease
Abstract
The Parkinson's disease (PD) research field has seen the advent of several promising biomarkers and a deeper understanding of the clinical features of the disease from the earliest stages of pathology to manifest disease. Despite progress, a biologically based PD staging system does not exist. Such staging would be a useful framework within which to model the disease, develop and validate biomarkers, guide therapeutic development, and inform clinical trials design. We propose that the presence of aggregated neuronal α-synuclein, dopaminergic neuron dysfunction/degeneration, and clinical signs and symptoms identifies a group of individuals that have Lewy body pathology, which in early stages manifests with what is now referred to as prodromal non-motor features and later stages with the manifestations of PD and related Lewy body diseases as defined by clinical diagnostic criteria. Based on the state of the field, we herein propose a definition and staging of PD based on biology. We present the biologic basis for such a staging system and review key assumptions and evidence that support the proposed approach. We identify gaps in knowledge and delineate crucial research priorities that will inform the ultimate integrated biologic staging system for PD.
Keywords: Parkinson’s disease; alpha-synuclein; biomarkers; disease staging.
Conflict of interest statement
The authors report no financial disclosures or conflicts of interest concerning the research related to the manuscript.
Tanya Simuni is an Editorial Board Member of this journal but was not involved in the peer-review process nor had access to any information regarding its peer-review.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10200239/bin/jpd-13-jpd225111-g001.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10200239/bin/jpd-13-jpd225111-g002.gif)
Similar articles
-
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2. Lancet Neurol. 2024. PMID: 38267190 Review.
-
Neuropathology of incidental Lewy body & prodromal Parkinson's disease.Mol Neurodegener. 2023 May 12;18(1):32. doi: 10.1186/s13024-023-00622-7. Mol Neurodegener. 2023. PMID: 37173733 Free PMC article. Review.
-
Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.Cent Nerv Syst Agents Med Chem. 2015;15(2):109-16. doi: 10.2174/1871524915666150421114338. Cent Nerv Syst Agents Med Chem. 2015. PMID: 25896035 Review.
-
A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.Biochim Biophys Acta. 2009 Jul;1792(7):730-40. doi: 10.1016/j.bbadis.2008.07.006. Epub 2008 Aug 5. Biochim Biophys Acta. 2009. PMID: 18718530 Review.
-
[Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].Rinsho Shinkeigaku. 2008 Jan;48(1):11-24. doi: 10.5692/clinicalneurol.48.11. Rinsho Shinkeigaku. 2008. PMID: 18386627 Review. Japanese.
Cited by
-
The regulating effect of curcumin on NF-κB pathway in neurodegenerative diseases: a review of the underlying mechanisms.Inflammopharmacology. 2024 May 20. doi: 10.1007/s10787-024-01492-1. Online ahead of print. Inflammopharmacology. 2024. PMID: 38769198 Review.
-
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson's disease.NPJ Parkinsons Dis. 2024 May 17;10(1):102. doi: 10.1038/s41531-024-00714-1. NPJ Parkinsons Dis. 2024. PMID: 38760408 Free PMC article.
-
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances.NPJ Parkinsons Dis. 2024 May 14;10(1):101. doi: 10.1038/s41531-024-00716-z. NPJ Parkinsons Dis. 2024. PMID: 38744872 Free PMC article.
-
How Lifetime Evolution of Parkinson's Disease Could Shape Clinical Trial Design: A Shared Patient-Clinician Viewpoint.Brain Sci. 2024 Apr 3;14(4):358. doi: 10.3390/brainsci14040358. Brain Sci. 2024. PMID: 38672010 Free PMC article.
-
Epidemiology of Parkinson's Disease: An Update.Curr Neurol Neurosci Rep. 2024 Jun;24(6):163-179. doi: 10.1007/s11910-024-01339-w. Epub 2024 Apr 20. Curr Neurol Neurosci Rep. 2024. PMID: 38642225 Review.
References
-
- Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29, 454–462. - PMC - PubMed
-
- Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30, 1591–1601. - PubMed
-
- Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schaffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB (2018) Movement disorder society criteria for clinically established early Parkinson’s disease. Mov Disord 33, 1643–1646. - PubMed
-
- Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB, MDS Task Force on the Definition of Parkinson’s Disease (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord 34, 1464–1470. - PubMed
-
- Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30, 1600–1611. - PubMed